Incyte Corp (NAS:INCY)
$ 57.05 -0.55 (-0.95%) Market Cap: 12.83 Bil Enterprise Value: 9.14 Bil PE Ratio: 17.29 PB Ratio: 2.38 GF Score: 88/100

Incyte Corp at Barclays Global Healthcare Conference Transcript

Mar 13, 2019 / 01:00PM GMT
Release Date Price: $85.06 (+0.19%)
Geoffrey Christopher Meacham
Barclays Bank PLC, Research Division - MD & Senior Research Analyst

Okay. Welcome to the morning sessions of the second day of the Barclays Health Care Conference. My name is Geoff Meacham, I'm the senior biopharma analyst. Jason Zemansky's with me on stage. We're really excited to have Incyte. And speaking on behalf of Incyte up here is Chairman and CEO, Hervé Hoppenot. Hervé, welcome.

HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO

© -

Good morning.

Questions & Answers

Geoffrey Christopher Meacham;HervÃ<
Barclays Bank PLC, Research Division - MD & Senior Research Analyst

So for the -- we'll kickoff today the conversation with the success that you guys have had for the Jakafi franchise. Can you just give us a sense kind for kind of the -- what you see as maybe the long-term trends when you look at the core indications, MF and PV and then maybe how much of a driver do you think commercially GVHD ultimately will be?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot